




Power endogenous T cells to bridge to cancer cells

FOR A VITAL CONNECTION



When treating cancer patients, connections matter—the connection from doctor to patient, from patient to caregiver, and especially from T cell to tumor. BiTE® is an off-the-shelf, targeted immuno-oncology platform that engages a patient's own T cells to any tumor-specific antigen, activating the T cell's cytotoxic potential and creating a connection that matters.

WE'RE BRINGING BiTE® TO THE FIGHT

**ENGAGE HIS
INNER STRENGTH.**



**TO TARGET
HIS TUMOR.**




AMGEN[®]
Oncology

When treating cancer patients, connections matter—the connection from doctor to patient, from patient to caregiver, and especially from T cell to tumor. BiTE[®] is an off-the-shelf, targeted immuno-oncology platform that engages a patient's own T cells to any tumor-specific antigen, activating the T cell's cytotoxic potential and creating a connection that matters.

WE'RE BRINGING BiTE[®] TO THE FIGHT

BiTE® engages and directs patients' own T cell to any tumor-specific antigen

BiTE® is ushering in the era of



immuno-intelligence



Today, cancer treatment requires a forward-thinking vision. BiTE® is an off-the-shelf immuno-oncology platform that engages and directs patients' own T cells to target any tumor-specific antigen. This groundbreaking technology activates the cytotoxic potential of T cells to eliminate cancer. We at Amgen are advancing immuno-oncology to immuno-intelligence.

WE'RE BRINGING IMMUNO-INTELLIGENCE TO THE FIGHT, WITH BiTE®

